Dihydropyrimidine Dehydrogenase Deficiency Test method(s): ◦ Genotyping (Microarray, Beads, etc.) bio.logis Center for Human Genetics - Frankfurt am Main, Germany |
iGene Pharmacogenetics method(s): ◦ Sequencing, Next Gen ApolloGen, Inc. - Irvine, CA, USA |
iGene Comprehensive Panel (Cancer, Cardiac, Drug Sensitivity) method(s): ◦ Sequencing, Next Gen ApolloGen, Inc. - Irvine, CA, USA |
Dihydropyrimidine Dehydrogenase Deficiency method(s): ◦ Genotyping (Microarray, Beads, etc.) ◦ Sequencing, Capillary (Sanger) ◦ Del/Dup (CNV) MVZ Dortmund Dr. Eberhard and Partner - Dortmund, Germany |
DPD Gene Sequencing and RFLP method(s): ◦ Genotyping (Microarray, Beads, etc.) ◦ Sequencing, Capillary (Sanger) Center for Human Genetics and Laboratory Medicine Martinsried, Molecular Genetics - Martinsried, Germany |
epiSEEK® Comprehensive Sequence Analysis for Epilepsy and Seizure Disorders method(s): ◦ Sequencing, Next Gen Courtagen Life Sciences, Courtagen Diagnostics Laboratory - Woburn, MA, USA |
nucSEEK® Comprehensive Sequence Analysis Of The Nuclear Mitochondrial Exome method(s): ◦ Sequencing, Next Gen Courtagen Life Sciences, Courtagen Diagnostics Laboratory - Woburn, MA, USA |
devACT Clinical Management Panel, Developmental Delay, Intellectual Disability, Autism Spectrum Disorders method(s): ◦ Sequencing, Next Gen Courtagen Life Sciences, Courtagen Diagnostics Laboratory - Woburn, MA, USA |
DPYD method(s): ◦ Genotyping (Microarray, Beads, etc.) Genelex Labs LLC - Seattle, WA, USA |
Susceptibility to Drugs (5-Fluoruracil), Sequencing DPYD Gene and Genotype (2R/2R,2R/3R,3R/3R) TYMS Gene method(s): ◦ Genotyping (Microarray, Beads, etc.) ◦ Sequencing, Capillary (Sanger) Reference Laboratory Genetics - Hospitalet de Llobregat, Spain |
Susceptibility to Drugs (5-Fluoruracil), Mutation (IVS14 +1 G>A) DPYD Gene method(s): ◦ Mutation Scanning of Entire Coding Region Reference Laboratory Genetics - Hospitalet de Llobregat, Spain |
Inherited Disease Panel method(s): ◦ Sequencing, Next Gen Genomic Laboratory of the DNA Research Center LTD (Centrum Badań DNA sp z o.o.) - Poznań, Poland |
Epilepsy Panel method(s): ◦ Sequencing, Next Gen Genomic Laboratory of the DNA Research Center LTD (Centrum Badań DNA sp z o.o.) - Poznań, Poland |
Comprehensive Panel: Developmental Delay, Intellectual Disability, Autism Spectrum Disorders method(s): ◦ Sequencing, Next Gen Genomic Laboratory of the DNA Research Center LTD (Centrum Badań DNA sp z o.o.) - Poznań, Poland |
Dihydropyrimidine dehydrogenase deficiency (sequence analysis of DPYD gene) method(s): ◦ Sequencing, Capillary (Sanger) CGC Genetics - Porto, Portugal |
5-fluorouracil toxicity (2 alleles on MTHFR, 1 allele on TYMS and 1 allele on DPYD genes) method(s): ◦ Sequencing, Capillary (Sanger) CGC Genetics - Porto, Portugal |
Toxicity to Fluoropyrimidines: DPYD gene and TYMS (2R / 2R, 2R / 3R o 3R / 3R) gene sequence analysis and genotype determination method(s): ◦ Sequencing, Capillary (Sanger) GENETAQ, Molecular Genetics Centre - Malaga, Spain |
DPYD Genotyping method(s): ◦ Genotyping (Microarray, Beads, etc.) Indiana University Pharmacogenomics Laboratory - Indianapolis, IN, USA |
Severe Recessive Childhood Diseases method(s): ◦ Sequencing, Next Gen MGZ München, Medizinisch Genetisches Zentrum München - München, Germany |
Metabolic Epilepsy Panel method(s): ◦ Sequencing, Next Gen CeGaT GmbH - Tübingen, Germany |
Somatic Tumor Panel method(s): ◦ Sequencing, Next Gen CeGaT GmbH - Tübingen, Germany |
Pan-Ethnic Carrier Screen: Gene Sequencing Panel method(s): ◦ Sequencing, Capillary (Sanger) ◦ Sequencing, Next Gen CEN4GEN Institute for Genomics and Molecular Diagnostics - Edmonton, Canada |
Pan-Ethnic Carrier Screen: Targeted Mutation Panel method(s): ◦ Sequencing, Capillary (Sanger) ◦ Sequencing, Next Gen CEN4GEN Institute for Genomics and Molecular Diagnostics - Edmonton, Canada |
DPYD Mutation Affecting 5-Fluorouracil Therapy method(s): ◦ Sequencing, Capillary (Sanger) GMDL Genica - Sofia, Bulgaria |
Dihydropyrimidine Dehydrogenase (DPYD), 3 Variants method(s): ◦ Genotyping (Microarray, Beads, etc.) ARUP Laboratories, Molecular Genetics Laboratory - Salt Lake City, UT, USA |
5-Fluorouracil (5-FU) Toxicity and Chemotherapeutic Response, 5 Mutations method(s): ◦ Genotyping (Microarray, Beads, etc.) ARUP Laboratories, Molecular Genetics Laboratory - Salt Lake City, UT, USA |
Epilepsy Exome Panel method(s): ◦ Sequencing, Next Gen University of Chicago, Genetic Services Laboratory - Chicago, IL, USA |
Dihydropyrimidine Dehydrogenase Deficiency (DPYD) method(s): ◦ Genotyping (Microarray, Beads, etc.) ◦ Sequencing, Next Gen Integrated Genetics, Molecular Diagnostic Laboratory - Westborough, MA, USA |
Pan-Ethnic Carrier Screen: Mutation and SMA Analysis method(s): ◦ Sequencing, Capillary (Sanger) ◦ Sequencing, Next Gen CEN4GEN Institute for Genomics and Molecular Diagnostics - Edmonton, Canada |
Pan-Ethnic Carrier Screen: Full Gene Sequencing and SMA Analysis method(s): ◦ Sequencing, Capillary (Sanger) ◦ Sequencing, Next Gen CEN4GEN Institute for Genomics and Molecular Diagnostics - Edmonton, Canada |
DPYD method(s): ◦ Sequencing, Next Gen ◦ Sequencing, Capillary (Sanger) ◦ Del/Dup (CNV) Fulgent Diagnostics - Temple City, CA, USA |
Intellectual Disability NGS Panel method(s): ◦ Sequencing, Next Gen ◦ Sequencing, Capillary (Sanger) ◦ Del/Dup (CNV) Fulgent Diagnostics - Temple City, CA, USA |
Lysosomal Disorders NGS Panel method(s): ◦ Sequencing, Next Gen ◦ Sequencing, Capillary (Sanger) ◦ Del/Dup (CNV) Fulgent Diagnostics - Temple City, CA, USA |
Dihydropyrimidine Dehydrogenase Deficiency: DPYD gene method(s): ◦ Sequencing, Capillary (Sanger) GenoMed-Diagnosticos de Medicina Molecular, SA - Lisboa, Portugal |
Comprehensive Epilepsy Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Capillary (Sanger) ◦ Sequencing, Next Gen Fulgent Diagnostics - Temple City, CA, USA |
Chemo DME Panel method(s): ◦ Genotyping (Microarray, Beads, etc.) Castle Medical, LLC - Smyrna, GA, USA |
TAT: 7-10 days price: $249.00
OneOme RightMed pharmacogenomic test method(s): ◦ Del/Dup (CNV) ◦ Genotyping (Microarray, Beads, etc.) OneOme - Minneapolis, MN, USA |
TAT: 1-2 weeks price: $560.00
KaryoNIM 180K Autism method(s): ◦ Microarray (CGH-Oligo, SNP, BAC) NIMGenetics Genomics & Medicine. (New Integrated Medical Genetics). - Madrid, Spain |
TAT: 3-4 weeks price: $690.00
Dihydropyrimidine Dehydrogenase Deficiency via the DPYD Gene method(s): ◦ Del/Dup (CNV) PreventionGenetics (Prevention Genetics), Clinical DNA Testing and DNA Banking - Marshfield, WI, USA |
TAT: 3-5 weeks price: $990.00
Dihydropyrimidine Dehydrogenase Deficiency via the DPYD Gene method(s): ◦ Sequencing, Next Gen PreventionGenetics (Prevention Genetics), Clinical DNA Testing and DNA Banking - Marshfield, WI, USA |
Dihydropyrimidine dehydrogenase deficiency method(s): ◦ Sequencing, Capillary (Sanger) Centogene AG, Rare Disease Company - Rostock, Germany |
Genelex Polypharmacy Comprehensive Panel method(s): ◦ Del/Dup (CNV) ◦ Genotyping (Microarray, Beads, etc.) Genelex Labs LLC - Seattle, WA, USA |
Pan-European Carrier Screening method(s): ◦ Sequencing, Next Gen MNG Laboratories (Medical Neurogenetics, LLC.) - Atlanta, GA, USA |
Treatable Seizures Spotlight Panel method(s): ◦ Sequencing, Next Gen Courtagen Life Sciences, Courtagen Diagnostics Laboratory - Woburn, MA, USA |
Dihydropyrimidine Dehydrogenase (DPYD) Full Gene Sequencing method(s): ◦ Sequencing, Capillary (Sanger) Mayo Clinic - Minnesota, Personalized Genomics Laboratory - Rochester, MN, USA |
CentoICU Platinum method(s): ◦ Sequencing, Next Gen Centogene AG, Rare Disease Company - Rostock, Germany |
Susceptibility to Drugs (5-Fluoruracil), Deletions-Duplications (MLPA) DPYD Gene method(s): ◦ Del/Dup (CNV) Reference Laboratory Genetics - Hospitalet de Llobregat, Spain |
Comprehensive Epilepsy Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, Helsinki - Helsinki, Finland |
Comprehensive Metabolism Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, Helsinki - Helsinki, Finland |
Lysosomal Disorders and Mucopolysaccharidosis Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, Helsinki - Helsinki, Finland |
Metabolic Epilepsy Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, Helsinki - Helsinki, Finland |
Comprehensive Epilepsy Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, San Francisco - San Francisco, CA, USA |
Comprehensive Metabolism Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, San Francisco - San Francisco, CA, USA |
Lysosomal Disorders and Mucopolysaccharidosis Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, San Francisco - San Francisco, CA, USA |
Metabolic Epilepsy Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, San Francisco - San Francisco, CA, USA |
GeneAware Complete Panel Version 2 (Female) method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Baylor Miraca Genetics Laboratories - Houston, TX, USA |
GeneAware Complete Panel Version 2 (Male) method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Baylor Miraca Genetics Laboratories - Houston, TX, USA |